PLANET-TRACKER
Access to Nutrition Initiative (ATNI) and Planet Tracker, in association with The Global Alliance for Improved Nutrition, have published a seminal Materiality of Nutrition Report. The first collaboration between ATNI and Planet Tracker sets the scene for a new conversation – how can healthier foods drive healthy profits, people and planet?
The report compares the healthiness of food product portfolios from 20 of the largest global food manufacturers with their profits and market valuations. The findings reveal a link between healthier food product portfolios and higher profitability but this is obscured by poor company disclosures.
Key Findings
NB: The sample size is only 20 companies. Neither ATNI nor Planet Tracker wish to suggest this report is more than a discussion paper to stimulate further debate.
Health & Profitability: Analysis shows that companies with broader, healthier food portfolios have higher average profit margins (15.2%) compared to those with unhealthy portfolios (13.4%). However, a subset specializing in unhealthy products, like soft drinks, shows even higher margins (16.7%), highlighting the complexity of the market.
Health Star Rating (HSR) and EBIT: Understanding the relationship between HSR and EBIT is key to drive investments towards health and wealth. Our findings suggest there is not a strong negative association, in the companies assessed, between HSR and EBIT. What’s more, our results suggest there are positive associations between HSR and EBIT among smaller companies with broad portfolios.
Investment Opportunities: In addition to the obvious benefits to society, investors would benefit from a switch to healthier foods. In a scenario where companies with unhealthy portfolios switch to healthier products and achieved similar margins, profits would also rise by nearly USD 350 million and valuations by USD 60 billion.
Investment risks: Most companies fail to provide sufficient information, making it difficult for investors to assess the impact of nutrition on their valuations. This lack of transparency is a missed opportunity for companies and a risk for investors, particularly with potential regulations on the horizon.
Social & Economic Impact: Unhealthy food products reduce productivity, increase costs for employers, and impose a significant burden on society, potentially reducing GDP by 3.3% and life expectancy by three years by 2050.
Policy & Regulation: Effective policy actions in various countries signal rising pressure for broader regulation, posing risks (and opportunities) or companies relying on unhealthy products and the financial institutions that support them.
Greg S Garrett, Executive Director, Access to Nutrition Initiative,
“This report is part of a small but critical and growing body of evidence showing that food companies should improve the healthiness of their portfolios and disclosures. By not doing so, they increase their own risk and miss the opportunity to improve societal outcomes.”
Peter Elwin, Head of the Food and Land Use programme at Planet Tracker,
“Unhealthy food products are costing society and employers, but the issue is being overlooked by financial institutions. Regulation presents an increasing threat to companies profiting from producing unhealthy foods, but poor disclosure is hiding the risks. Our analysis shows that there could be investment opportunities associated with producing healthy food so there’s an incentive for investors to ask for change.”
Read the report here.
About ATNI
ATNI is a global non-profit founded in 2013 that exists for the sole purpose of transforming markets for nutrition. ATNI believes the private sector has an important role to play in fighting malnutrition. ATNI’s mission is to improve (financial) market performance by challenging key actors in the food system – notably industry and investors – to accelerate access to affordable, sustainable, and nutritious food for all, especially for society’s most vulnerable. ATNI does this through the development and publication of accountability tools and strategies in close collaboration with industry, investors, policymakers, consumers organizations and other nutrition stakeholders.
About Planet Tracker
Planet Tracker is an award-winning non-profit financial think tank aligning capital markets with planetary boundaries. Created with the vision of a financial system that is fully aligned with a net-zero, resilient, nature positive and just economy well before 2050, Planet Tracker generates break-through analytics that reveal both the role of capital markets in the degradation of our ecosystem and show the opportunities of transitioning to a zero-carbon, nature positive economy.
About GAIN
The Global Alliance for Improved Nutrition (GAIN) is a Swiss-based foundation launched at the United Nations in 2002 to tackle the human suffering caused by malnutrition. Working with governments, businesses and civil society, GAIN aims to transform food systems so that they deliver more nutritious foods for all people, especially the most vulnerable.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240626413872/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
